Synthesis and evaluation of haloperidol metabolite II prodrugs as anticancer agents. 2017

Maria Dichiara, and Emanuele Amata, and Antonio Rescifina, and Orazio Prezzavento, and Giuseppe Floresta, and Carmela Parenti, and Valeria Pittalà, and Agostino Marrazzo
Dipartimento di Scienze del Farmaco, Università di Catania, Viale Andrea Doria 6, 95125 Catania, Italy.

The use of haloperidol metabolite II (HP-metabolite II) prodrugs is an emerging strategy in the treatment of cancer. HP-metabolite II exhibits antiproliferative properties at micromolar concentrations inducing apoptosis in different types of cancer. Thus, the application of the prodrug approach appears as a useful method leading to much more desirable pharmacokinetic and pharmacodynamic properties. Some studies have shown that the esterification of the hydroxyl group of HP-metabolite II with 4-phenylbutiric acid (4-PBA) or valproic acid enhances the anticancer therapeutic potency. The current progresses in the design, synthesis and evaluation of anticancer activity of HP metabolite II prodrugs will be discussed in this review.

UI MeSH Term Description Entries
D010654 Phenylbutyrates Derivatives of 4-phenylbutyric acid, including its salts and esters.
D011355 Prodrugs A compound that, on administration, must undergo chemical conversion by metabolic processes before becoming the pharmacologically active drug for which it is a prodrug. Drug Precursor,Drug Precursors,Pro-Drug,Prodrug,Pro-Drugs,Precursor, Drug,Precursors, Drug,Pro Drug,Pro Drugs
D002470 Cell Survival The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability. Cell Viability,Cell Viabilities,Survival, Cell,Viabilities, Cell,Viability, Cell
D006220 Haloperidol A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279) Haldol
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D014635 Valproic Acid A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS. Dipropyl Acetate,Divalproex,Sodium Valproate,2-Propylpentanoic Acid,Calcium Valproate,Convulsofin,Depakene,Depakine,Depakote,Divalproex Sodium,Ergenyl,Magnesium Valproate,Propylisopropylacetic Acid,Semisodium Valproate,Valproate,Valproate Calcium,Valproate Sodium,Valproic Acid, Sodium Salt (2:1),Vupral,2 Propylpentanoic Acid
D015398 Signal Transduction The intracellular transfer of information (biological activation/inhibition) through a signal pathway. In each signal transduction system, an activation/inhibition signal from a biologically active molecule (hormone, neurotransmitter) is mediated via the coupling of a receptor/enzyme to a second messenger system or to an ion channel. Signal transduction plays an important role in activating cellular functions, cell differentiation, and cell proliferation. Examples of signal transduction systems are the GAMMA-AMINOBUTYRIC ACID-postsynaptic receptor-calcium ion channel system, the receptor-mediated T-cell activation pathway, and the receptor-mediated activation of phospholipases. Those coupled to membrane depolarization or intracellular release of calcium include the receptor-mediated activation of cytotoxic functions in granulocytes and the synaptic potentiation of protein kinase activation. Some signal transduction pathways may be part of larger signal transduction pathways; for example, protein kinase activation is part of the platelet activation signal pathway. Cell Signaling,Receptor-Mediated Signal Transduction,Signal Pathways,Receptor Mediated Signal Transduction,Signal Transduction Pathways,Signal Transduction Systems,Pathway, Signal,Pathway, Signal Transduction,Pathways, Signal,Pathways, Signal Transduction,Receptor-Mediated Signal Transductions,Signal Pathway,Signal Transduction Pathway,Signal Transduction System,Signal Transduction, Receptor-Mediated,Signal Transductions,Signal Transductions, Receptor-Mediated,System, Signal Transduction,Systems, Signal Transduction,Transduction, Signal,Transductions, Signal
D017480 Receptors, sigma A class of cell surface receptors recognized by its pharmacological profile. Sigma receptors were originally considered to be opioid receptors because they bind certain synthetic opioids. However they also interact with a variety of other psychoactive drugs, and their endogenous ligand is not known (although they can react to certain endogenous steroids). Sigma receptors are found in the immune, endocrine, and nervous systems, and in some peripheral tissues. Opioid Receptors, sigma,Receptors, Opioid, sigma,Receptors, sigma Opioid,sigma Receptors,sigma Receptor,Receptor, sigma,sigma Opioid Receptors
D056572 Histone Deacetylase Inhibitors Compounds that inhibit HISTONE DEACETYLASES. This class of drugs may influence gene expression by increasing the level of acetylated HISTONES in specific CHROMATIN domains. HDAC Inhibitor,HDAC Inhibitors,Histone Deacetylase Inhibitor,Deacetylase Inhibitor, Histone,Deacetylase Inhibitors, Histone,Inhibitor, HDAC,Inhibitor, Histone Deacetylase,Inhibitors, HDAC,Inhibitors, Histone Deacetylase

Related Publications

Maria Dichiara, and Emanuele Amata, and Antonio Rescifina, and Orazio Prezzavento, and Giuseppe Floresta, and Carmela Parenti, and Valeria Pittalà, and Agostino Marrazzo
August 2009, Journal of medicinal chemistry,
Maria Dichiara, and Emanuele Amata, and Antonio Rescifina, and Orazio Prezzavento, and Giuseppe Floresta, and Carmela Parenti, and Valeria Pittalà, and Agostino Marrazzo
April 2017, Bioorganic chemistry,
Maria Dichiara, and Emanuele Amata, and Antonio Rescifina, and Orazio Prezzavento, and Giuseppe Floresta, and Carmela Parenti, and Valeria Pittalà, and Agostino Marrazzo
November 1981, Journal of pharmaceutical sciences,
Maria Dichiara, and Emanuele Amata, and Antonio Rescifina, and Orazio Prezzavento, and Giuseppe Floresta, and Carmela Parenti, and Valeria Pittalà, and Agostino Marrazzo
January 2015, Anti-cancer agents in medicinal chemistry,
Maria Dichiara, and Emanuele Amata, and Antonio Rescifina, and Orazio Prezzavento, and Giuseppe Floresta, and Carmela Parenti, and Valeria Pittalà, and Agostino Marrazzo
June 2021, Molecules (Basel, Switzerland),
Maria Dichiara, and Emanuele Amata, and Antonio Rescifina, and Orazio Prezzavento, and Giuseppe Floresta, and Carmela Parenti, and Valeria Pittalà, and Agostino Marrazzo
March 2014, Indian journal of pharmaceutical sciences,
Maria Dichiara, and Emanuele Amata, and Antonio Rescifina, and Orazio Prezzavento, and Giuseppe Floresta, and Carmela Parenti, and Valeria Pittalà, and Agostino Marrazzo
May 2009, Bioorganic & medicinal chemistry letters,
Maria Dichiara, and Emanuele Amata, and Antonio Rescifina, and Orazio Prezzavento, and Giuseppe Floresta, and Carmela Parenti, and Valeria Pittalà, and Agostino Marrazzo
September 2023, Dalton transactions (Cambridge, England : 2003),
Maria Dichiara, and Emanuele Amata, and Antonio Rescifina, and Orazio Prezzavento, and Giuseppe Floresta, and Carmela Parenti, and Valeria Pittalà, and Agostino Marrazzo
October 2013, Bioorganic & medicinal chemistry letters,
Maria Dichiara, and Emanuele Amata, and Antonio Rescifina, and Orazio Prezzavento, and Giuseppe Floresta, and Carmela Parenti, and Valeria Pittalà, and Agostino Marrazzo
May 2008, Bioorganic & medicinal chemistry,
Copied contents to your clipboard!